Phase 1 dose escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer-Lack of association between activating AKT mutation and AKT inhibition-derived efficacy

Authors

Andreas Schneeweiss, University Hospital Heidelberg and German Cancer Research Center
Dagmar Hess, Kantonsspital St. Gallen
Markus Joerger, Kantonsspital St. Gallen
Andrea Varga, Institut Gustave Roussy
Stacy Moulder, The University of Texas MD Anderson Cancer Center
Apostolia M Tsimberidou, The University of Texas MD Anderson Cancer Center
Cynthia Ma, Washington University School of Medicine in St. Louis
Sara A Hurvitz, University of California, Los Angeles
Christine Rentzsch, Bayer AG
Marion Rudolph, Bayer AG
Silke Thiele, Bayer AG
Oliver Boix, Bayer AG
Gary Wilkinson, Bayer AG
Eleni Lagkadinou, Bayer AG
Matthias Ocker, Bayer AG

Journal

Cancers (Basel)

Publication Date

2019

Volume

11

Issue

12

First Page

1987

Document Type

Open Access Publication

DOI

10.3390/cancers11121987

Rights and Permissions

Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkinson G, Lagkadinou E, Ocker M. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers. 2019; 11(12):1987. doi: 10.3390/cancers11121987.

Recommended Citation

Schneeweiss, Andreas; Hess, Dagmar; Joerger, Markus; Varga, Andrea; Moulder, Stacy; Tsimberidou, Apostolia M; Ma, Cynthia; Hurvitz, Sara A; Rentzsch, Christine; Rudolph, Marion; Thiele, Silke; Boix, Oliver; Wilkinson, Gary; Lagkadinou, Eleni; and Ocker, Matthias, "Phase 1 dose escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer-Lack of association between activating AKT mutation and AKT inhibition-derived efficacy." Cancers (Basel). 11, 12. 1987 (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8587